"Machi" 20th Rolling Position: Experienced 20 Liquidations and 8 Additional Fund Injections, Principal Has Now Doubled
BlockBeats news, on March 16, according to Hyperinsight monitoring, "Maji" Huang Licheng transferred $250,000 to Hyperliquid on February 28, launching the "20th round of rolling long ETH positions." During this round, he made a total of 8 additional deposits and was liquidated 20 times, totaling $1.16 million.
As the market has recently recovered, his account funds have risen to $2.19 million, nearly doubling his principal. Reviewing his position trajectory:
February 28 (first day of opening positions): suffered 4 liquidations;
March 1 to 3: 13 long positions were forcibly liquidated within three days, and the account funds once dropped to only $8,700;
March 8 to 9: another 3 large liquidations.
Until March 10, this address deposited funds again, and continued to go long ETH after it fell below $2,000, accumulating positions down to $1,950, eventually capturing this round of rebound.
This address may be aiming for a major rebound or the start of a bull market. From last October to now, nearly 5 months, he has attempted to go long various tokens nearly 170 times, including 20 rounds of rolling long ETH positions, with a net deposit of about $16.84 million into Hyperliquid.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
